Louie Naumovski

Louie joins Genesis with 30+ years of experience, with an extensive track record in early clinical development of novel oncology drugs, including small molecules, antibodies, antibody drug conjugates (ADCs) and novel biologics. Most recently, he served as CMO at Arch Oncology. Prior to that, at Abbvie, Genentech BioOncology, and Pharmacyclics, he held various roles responsible for developing the strategy, design and implementation of IND filings and Phase I/II clinical trials of ADCs and other drugs in the Oncology/Immunology spaces. He holds M.D. and Ph.D in Cancer Biology from Stanford University.